Results 11 to 20 of about 133,829 (277)
RANK and RANK ligand expression in primary human osteosarcoma [PDF]
Journal of Bone Oncology, 2015 Receptor activator of nuclear factor kappa-B ligand (RANKL) is an essential mediator of osteoclast formation, function and survival. In patients with solid tumor metastasis to the bone, targeting the bone microenvironment by inhibition of RANKL using ...
Daniel Branstetter +7 more
doaj +6 more sources
RANK-Ligand inhibitor associated osteonecrosis of the jaw [PDF]
GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2013 Osteonecrosis of the jaw may be caused by many different triggers. One of them is described to be the drug or medication related osteonecrosis of the jaw. Since many years bisphosphonates induced the dreaded diagnosis.
Rashad, Ashkan +2 more
doaj +7 more sources
Correlating RANK Ligand/RANK Binding Kinetics With Osteoclast Formation and Function [PDF]
Journal of Cellular Biochemistry, 2015 ABSTRACTThe interaction between Receptor Activator of NF‐κB Ligand (RANKL) and its receptor RANK is essential for the differentiation and bone resorbing capacity of the osteoclast. Osteoprotegerin (OPG), a soluble homodimer, acts as a decoy receptor for RANKL and thus inhibits osteoclastogenesis.
Steven Teitelbaum +2 more
exaly +5 more sources
OPG, RANK and RANK ligand expression in thyroid lesions [PDF]
Regulatory Peptides, 2008 Receptor activator of NF-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) play essential roles in bone metabolism. RANKL binds to RANK, which is expressed by osteoclasts whereas OPG acts as its decoy receptor blocking the RANK-RANKL interaction.
Dominique Heymann +2 more
exaly +5 more sources
DeepBindPoc: a deep learning method to rank ligand binding pockets using molecular vector representation [PDF]
PeerJ, 2020 Accurate identification of ligand-binding pockets in a protein is important for structure-based drug design. In recent years, several deep learning models were developed to learn important physical–chemical and spatial information to predict ligand ...
Haiping Zhang +6 more
doaj +5 more sources
Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition [PDF]
Journal of Investigative Medicine High Impact Case Reports, 2014 Lung metastases are a rare complication of giant cell tumors of bone. We herein describe an interesting case of histological regression and size reduction of lung metastases originating from a primary giant cell tumor of bone in response to the RANK ...
Martin F. Dietrich MD, PhD +3 more
doaj +3 more sources
The role of RANK ligand/osteoprotegerin in rheumatoid arthritis [PDF]
Therapeutic Advances in Musculoskeletal Disease, 2012 In the complex system of bone remodeling, the receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) pathway is the coupling factor between bone formation and bone resorption. RANKL binds to the RANK receptor of pre-osteoclasts and mature osteoclasts and stimulates their activation and differentiation.
Piet Geusens
exaly +5 more sources
Changes in Serum Dickkopf-1, RANK Ligand, Osteoprotegerin, and Bone Mineral Density after Allogeneic Hematopoietic Stem Cell Transplantation Treatment [PDF]
Endocrinology and Metabolism, 2021 Background Dickkopf-1 (DKK1) regulates bone formation by inhibiting canonical Wnt/β-catenin pathway signaling, and indirectly enhances osteoclastic activity by altering the expression ratio of receptor activator of nuclear factor-κB ligand (RANKL ...
Eunhee Jang +3 more
doaj +2 more sources
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients [PDF]
Clinical Interventions in Aging, 2012 Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast ...
Yee AJ, Raje NS
doaj +4 more sources
RANK and RANK Ligand Expression in Parotid Gland Carcinomas [PDF]
Applied Immunohistochemistry & Molecular Morphology, 2018 Recently, it has been reported that deregulation of the receptor activator of NFkB ligand (RANKL)/RANK signaling axis results in salivary gland tumor development in a mouse transgenic model. The aim of this study was to ascertain RANKL and RANK protein expression in a series of primary parotid gland carcinomas and to correlate it with clinicopathologic
Franchi A +6 more
openaire +6 more sources